Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors

Despite recent advances in both technology and molecular targeting, little progress has been made in the management of most malignancies of the brain, especially brain metastases. In an effort to increase the therapeutic ratio of external beam radiation treatments, radiosensitizers and enhancers have been investigated. Motexafin gadolinium is a new drug with radioenhancing properties and a unique mechanism of action that may increase the therapeutic index of whole brain radiotherapy for patients with brain metastases. The rationale for the use of this drug as well as its current and future role as a radiation enhancer in the management of brain tumors is reviewed.

[1]  D. Carbone,et al.  Reversible Renal Toxicity Resulting From High Single Doses of the New Radiosensitizer Gadolinium Texaphyrin , 2000, American journal of clinical oncology.

[2]  S. Rockwell,et al.  Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. , 2004, International journal of radiation oncology, biology, physics.

[3]  T. Phillips,et al.  A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). , 1991, International journal of radiation oncology, biology, physics.

[4]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[5]  A H Russell,et al.  Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). , 1998, International journal of radiation oncology, biology, physics.

[6]  R Timmerman,et al.  Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Prados,et al.  A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. , 1999, International journal of radiation oncology, biology, physics.

[8]  R. Shi,et al.  Survival in Relation to Radiotherapeutic Modality for Brain Metastasis: Whole Brain Irradiation vs. Gamma Knife Radiosurgery , 2004, American journal of clinical oncology.

[9]  E. Shaw,et al.  Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Sessler,et al.  Preclinical Evaluation of Gadolinium (III) Texaphyrin Complex: A New Paramagnetic Contrast Agent for Magnetic Resonance Imaging , 1994, Investigative radiology.

[11]  W. Curran,et al.  Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J A Koutcher,et al.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. , 1999, International journal of radiation oncology, biology, physics.

[13]  K. Carson,et al.  Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[15]  E. Shaw,et al.  RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Sessler,et al.  Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. Curran,et al.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Rowinsky.  Novel radiation sensitizers targeting tissue hypoxia. , 1999, Oncology.

[19]  W. Curran,et al.  Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Mehta,et al.  Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. , 2001, Cancer research.

[21]  J. Sessler,et al.  Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. , 2000, Biochemical pharmacology.

[22]  P. Rodrigus.  Motexafin gadolinium: a possible new radiosensitiser , 2003, Expert opinion on investigational drugs.

[23]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[24]  W. Curran,et al.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Vanel,et al.  Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. , 1999, Radiology.

[26]  C. Mcginn,et al.  The mechanism of action of radiosensitization of conventional chemotherapeutic agents. , 2003, Seminars in radiation oncology.

[27]  W. Semmler,et al.  Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent Gadobutrol. , 1999, Investigative radiology.

[28]  W. Curran,et al.  Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater results of radiation therapy oncology group 85–28 , 1993, Cancer.